每经AI快讯，8月11日，*ST苏吴(600200.SH)公告称，公司控股孙公司达透医疗器械（上海）有限公司 就Regen Biotech, Inc.违约事项向深圳国际仲裁院提起仲裁，并于2025年8月7日获得受理立案。达透医疗 请求确认《独家代理协议》有效并继续履行，若未得到支持，初步索赔损失人民币16亿元。仲裁结果存 在不确定性，且不排除被申请人提出反请求。此外，公司股票因收到《行政处罚事先告知书》被叠加实 施退市风险警示，可能存在炒作风险。 ...

Core Points - GDC Technology Limited's subsidiary ESPEDEO HOLDINGS LIMITED has initiated arbitration against Hong Kong Guangfeng, claiming at least $3.1671 million, which has since increased to $31.0235 million [1][2] - Guangfeng Technology has publicly disclosed the arbitration matter on multiple occasions, indicating that the products involved were custom-developed for ESPEDEO and that the contract includes a cap on compensation [1] - Guangfeng Technology asserts that the arbitration will not significantly impact its ongoing operations and has formed a legal team to defend its rights [1] Summary by Sections - **Arbitration Details** - ESPEDEO filed for arbitration in June 2024, initially claiming $3.1671 million, which was later raised to $31.0235 million in August 2025 [1] - The involved products were specifically developed for ESPEDEO, and the contract contains a clear limitation on compensation [1] - **Company's Response** - Guangfeng Technology has stated that the arbitration will not have a major adverse effect on its business operations and is actively preparing a legal defense [1] - The company emphasizes that the final impact will depend on the arbitration ruling or any potential settlement [1] - **Legal Perspective** - A legal expert noted that the sudden increase in the claim amount after a year could be seen as an attempt to disrupt the company's operations and waste judicial resources [2] - The contract's limitation on compensation may suggest that the increased claim is more about litigation tactics than legitimate damages [2]